Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.6%

15 terminated/withdrawn out of 129 trials

Success Rate

77.9%

-8.6% vs industry average

Late-Stage Pipeline

22%

29 trials in Phase 3/4

Results Transparency

74%

39 of 53 completed trials have results

Key Signals

15 recruiting39 with results11 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

41(46.6%)

Phase 3

29(33.0%)

N/A

14(15.9%)

Phase 1

3(3.4%)

Early Phase 1

1(1.1%)

88Total

Phase 2(41)

Phase 3(29)

N/A(14)

Phase 1(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (129)

Showing 20 of 129 trials

NCT02595424Phase 2Active Not Recruiting

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Role: lead

NCT02445391Phase 3Active Not Recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Role: lead

NCT07852195Phase 2Not Yet Recruiting

Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

Role: lead

NCT04438382Phase 2Terminated

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Role: lead

NCT01824875Phase 2Completed

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Role: lead

NCT00003641Phase 3Completed

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Role: lead

NCT03516942Active Not Recruiting

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

Role: lead

NCT06475989Phase 3Recruiting

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Role: lead

NCT05863195Phase 3Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Role: lead

NCT07068074Phase 3Recruiting

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Role: lead

NCT04467021Not ApplicableActive Not Recruiting

Cancer and Blood Pressure Management, CARISMA Study

Role: lead

NCT05538663Phase 3Active Not Recruiting

Intravesical BCG vs GEMDOCE in NMIBC

Role: lead

NCT07040280Phase 2Recruiting

Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Role: lead

NCT03516279Phase 2Active Not Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Role: lead

NCT04462406Phase 2Active Not Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Role: lead

NCT05863351Phase 3Active Not Recruiting

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Role: lead

NCT03804255Withdrawn

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

Role: lead

NCT03697148Not ApplicableActive Not Recruiting

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer

Role: lead

NCT03115333Not ApplicableActive Not Recruiting

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Role: lead

NCT06002828Active Not Recruiting

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Role: lead